Research Article

Gender Features of the Prevalence, Development and Progression of Left Ventricle Hypertrophy in Chronic Kidney Disease

I.T. Murkamilov1,2,* I.S. Sabirov3, V.V. Fomin4, Zh.A. Murkamilova2, K.A. Aitbaev4, F.A. Yusupov5, N.A. Redzhapova5, Z.R. Rayimzhanov6 and Z.A. Aidarov1

1Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan
2Kyrgyz Russian Slavic University, Bishkek, Kyrgyzstan
3First Moscow State Medical University, Moscow, Russia
4Scientific and Research Institute of Molecular Biology and Medicine, Bishkek, Kyrgyzstan
5Osh State University, Osh, Kyrgyzstan

ARTICLE INFO

Article history:
Received: 1 April, 2020
Accepted: 14 April, 2020
Published: 22 April, 2020

Keywords:
Chronic kidney disease
left ventricular hypertrophy
prevalence
cardiovascular disease
genre differences

ABSTRACT

Aim of the Study: To study the features of the prevalence of left ventricular hypertrophy in chronic kidney disease, taking into account gender differences.

Materials and Methods: This was an instant study. We examined 945 patients (360 female and 585 male) with chronic kidney disease (CKD) from the 1st to the 5th stage of the disease. The average age of the patients was 39.0±13.0 years. Glomerular filtration rate (GFR) was calculated using the CKD-EPI formula.

Results: In patients with female CKD, a significant decrease in hemoglobin, erythrocyte count, and eGFR was detected compared with males, while the incidence of hyperuricemia was significantly higher. Daily proteinuria was significantly higher in men compared with women. The prevalence of LVH was significantly higher in females compared with men (49.4% versus 35.7%; p<0.05). In women and men, the eccentric type prevailed in the structure of LVH. The number of patients with an eccentric type of LVH was significantly higher in the subgroup of females (p<0.05), and with concentric remodeling of the LV were significantly higher in males (p<0.05).

Conclusion: The prevalence of LVH among the examined individuals with CKD was 40.9%. Among women, the most common type of LVH was the eccentric type of remodeling (79.2%), and among men, the concentric type of LVH was 39.7% of cases.

© 2020 I.T. Murkamilov. by Science Repository. All rights reserved.

Introduction

The number of patients with chronic kidney disease (CKD) is growing worldwide, while patients with impaired renal function are at high or very high risk for developing cardiovascular disease (CVD) [1-3]. Mortality due to CVD in patients with CKD is 10–20 times higher than that in the general population, and the likelihood of developing cardiovascular complications (CVC) is several times higher than the risk of end-stage CKD [1-3]. According to the definition of cardiorenal syndrome of type 4, kidney disease is detected before the development of heart failure, although the timing of the diagnosis is not always possible [4]. Left ventricular hypertrophy (LVH) is a key feature that allows you to get an accurate picture of systolic-diastolic lesions of the left heart in patients with CKD and therefore is one of the most important factors in the development of adverse CVC in CKD [5, 6]. LVH is associated with increased mortality and the risk of adverse outcomes, especially at the terminal stage of CKD [7, 8].

Following an increase in pressure in the hypertrophied left ventricle against the background of diastolic myocardial dysfunction, the left
atrium expands very quickly [8]. This leads to the occurrence of supraventricular extrasystole, flutter and atrial fibrillation in patients with CKD with arterial hypertension (AH) [9]. In patients with concentric LV remodeling, a normal level of end systolic myocardial stress and an increase in peripheral vascular resistance are noted. At the same time, with concentric LV remodeling, a reduced shock index is observed. It has been established that patients with concentric LVH have normal sizes and LV shape, but increased total peripheral vascular resistance and a slight increase in cardiac index [10]. Persons with eccentric LVH are characterized by a high cardiac index and expansion of the LV cavity. A recent study shows that the prevalence of LVH is higher in a population of people with CKD [5, 11, 12].

**Aim of the Study**

To study the prevalence of left ventricular hypertrophy in chronic kidney disease, taking into account gender characteristics.

**Material and Methods**

A total of 945 CKD patients (585 men and 360 women; middle age 39.0 ± 13.0 years) aged 16–74 years were examined. CKD syndrome was established based on criteria proposed by KDIGO (Kidney Disease: Improving Global Outcomes) in 2002 [13]. In all cases, the cause of CKD was chronic glomerulonephritis and tubulointerstitial nephritis. Persons with primary arterial hypertension (AH), urethiasis, gout, diabetes mellitus, and patients undergoing hemodialysis therapy were excluded from the study. The examination of patients was complex using clinical, laboratory and instrumental methods. Type of study - one-stage. Laboratory studies included the determination of hemoglobin (Hb), the number of red blood cells, uric acid (UA), total and C-reactive protein (CRP), sodium, potassium, calcium, total cholesterol (TC), blood creatinine and daily proteinuria. The functional state of the kidneys was determined by the formula CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) [14].

According to the available recommendations, the criterion of hyperuricemia for males was taken to have a blood plasma UA content of more than 0.42 mmol/l, for women - more than 0.36 mmol/l [15]. Levels of CRP greater than 5 mg/L were considered elevated. The left ventricle mass (LVM) was calculated from the formula designated as the standard of the American Society of Echocardiography and derived from R.B.Devereux et al. [16]. This formula is LVM=0.8 [1.04 \((IVST+LVIDd+PWT)− LVID3\)] +0.6 g, where LVIDd is the left ventricular internal diameter in diastole, IVST the interventricular septal thickness, and PWT the posterior wall thickness. The criteria for left ventricular hypertrophy (LVH) and types of structural changes in the myocardium were determined in accordance with the recommendations of the European Society of Cardiology (ESC) from 2013 [17].

To assess LVH, LV mass index (LVMi) was calculated, the upper norm of which was 95 g/m² for women and 115 g/m² for men. The relative wall thickness (RWT) of the LV was calculated for each patient according to the formula (IVST+PWT)/LVIDd. An increase in RWT was taken to be more than 0.42 [17]. Depending on the size of LVMi and RWT, the following types of structural state of LV geometry were distinguished: normal LV geometry (RWT <0.42; normal LVMi), concentric remodeling (RWT >0.42; normal LVMi), concentric hypertrophy (RWT >0.42; LVMi is greater than normal), eccentric hypertrophy (RWT <0.42; LVMi is higher than normal).

**Statistical Analysis**

Statistical processing of the material was carried out using the licensed software package “Statistical 10.0”. The significance of differences between groups was assessed using t - Student's test (for variables with a normal distribution) and the Mann-Whitney test (for variables with a nonparametric distribution). The data are presented as mean ± standard deviation for variables with normal distribution, median (25% -75%) for variables with nonparametric distribution. To assess the correlation relationship, the Pearson method was used. The level of statistical significance was considered the value p <0.05.

**Results**

This study was aimed primarily at studying the prevalence of LVH in patients with CKD depending on gender differences. Table 1 shows the distribution of the examined patients according to the severity of CKD. It follows that the faces of CKD with C1, C2 and C5 stages were numerous in the general group. In the subgroup of men, persons with C1 stage of CKD predominated significantly (40.8%), whereas, in women, C4 stage of CKD was significantly higher (19.7%).

**Table 1: Clinical characteristics of patients included in the study.**

| CKD stages | Total, n=945 | Female (n=360) | Male (n=585) | p < |
|-------------|--------------|----------------|--------------|-----|
| C1, n(%)    | 327 (34.6)   | 88 (24.4)      | 239 (40.9)   | 0.05 |
| C2, n(%)    | 152 (16.1)   | 62 (17.2)      | 90 (15.4)    | 0.41 |
| C3a, n(%)   | 68 (7.2)     | 28 (7.8)       | 40 (6.8)     | 0.11 |
| C3b, n(%)   | 80 (8.4)     | 37 (10.3)      | 43 (7.3)     | 0.23 |
| C4, n(%)    | 138 (14.6)   | 71 (19.7)      | 67 (11.5)    | 0.05 |
| C5, n(%)    | 180 (19.1)   | 74 (20.6)      | 106 (18.1)   | 0.25 |

CKD: chronic kidney disease; C: stage; p: is the reliability; n: is the number of patients.

Table 2 shows that no intergroup differences in age, body mass index and hemodynamic parameters were obtained. It is important to underline that the peripheral blood indices significantly differed between the subgroups (Table 2). In particular, a statistically significant decrease in hemoglobin content (116.5 ± 25.5 g/l versus 130.9 ± 29.9 g/l; p <0.01) and the number of red blood cells (4.02 ± 0.64x10¹²/l versus 4.33 ± 0.72x10¹²/l; p <0.01) were observed in a subgroup of female persons. It is noteworthy that the concentration of iron in blood plasma between the compared subgroups did not significantly differ.

At the same time, there were no differences between the subgroups in the content of potassium, calcium, sodium, TC, and creatinine in blood plasma (Table 2). The incidence of hyperuricemia was significantly higher in women compared with men (74.1% versus 64.6%; p <0.05). Attention is also drawn to indicators of the nitrogen-excreting function of the kidneys in the studied cohorts. So, in the subgroup of females there was a statistically significant decrease in eGFR [49.9 (20.0-86.7) ml/min versus 56.0 (22.5-104.6) ml/min; p <0.05]. The daily urinary protein excretion was significantly higher in men compared with women [2.067 (0.716-4.600) g versus 1.562 (0.609-3.504) g; p <0.05].
Table 2: Clinical and laboratory characteristics of patients included in the study (n=945).

| Parameter                          | Female (n=360) | Male (n=585) | p <   |
|------------------------------------|---------------|-------------|-------|
| Age                                | 40.0±12.5     | 38.4±13.7   | 0.07  |
| Body mass index, kg / m²            | 26.2±5.74     | 25.9±6.1    | 0.48  |
| Heart rate, beats in minutes        | 78±9          | 77±11       | 0.11  |
| Systolic blood pressure, mmHg       | 140±29        | 143±26      | 0.10  |
| Diastolic blood pressure, mmHg      | 88±16         | 90±15       | 0.08  |
| Hemoglobin, g / l                   | 116.5±25.7    | 130.9±29.9  | 0.01  |
| Red blood cells, x10¹²/l            | 4.02±0.64     | 4.33±0.72   | 0.01  |
| Potassium, mmol / l                 | 4.69±0.73     | 4.76±0.82   | 0.24  |
| Calcium, mmol / l                   | 1.31±0.39     | 1.32±0.31   | 0.91  |
| Sodium, mmol / l                    | 138.1±25.5    | 139.1±29.5  | 0.06  |
| Total protein, g / l                | 58.7±11.4     | 56.3±14.7   | 0.01  |
| Iron, µmol / l                      | 15.2±5.4      | 17.4±4.0    | 0.07  |
| Total cholesterol, mmol / l         | 5.71±1.34     | 5.74±1.70   | 0.91  |
| Hyperuricemia, n (%)                | 267 (74.1)    | 378 (64.6)  | 0.05  |
| CRP >5 mg / l, n (%)                | 178 (49.4)    | 305 (52.1)  | 0.06  |
| Creatinine, µmol / l *              | 140.0 (84, 5-322.0) | 139.0 (89, 0-377.0) | 0.07  |
| eGFR, ml / min *                    | 49.9 (20, 0-86.7) | 56.0 (22, 5-104.6) | 0.05  |
| Proteinuria, g / day *              | 1.562 (0.609-3.504) | 2.067 (0.716-4.600) | 0.01  |

CRP: C-reactive protein; eGFR: estimated glomerular filtration rate; * - data are presented as median (25%-75%); p: is the reliability; n = is the number of patients.

The next step in the study was to analyze the prevalence of LVH according to echocardiography. In general, the prevalence of LVH was significantly higher in women compared with men (49.4% versus 35.7%). The thickness of the RWT and the number of patients with concentric remodeling of the LV were significantly greater in males (Table 3), and the number of people with an eccentric type of LVH was significantly higher in the subgroup of females (Table 3). It should be noted that in patients with CKD both in the subgroup of women and in the subgroup of men, eccentric types prevailed in the structure of LVH. As for the concentric type of LVH, it was significantly more often detected among males, which was accompanied by a significant decrease in the number of patients with normal LV geometry (Table 3).

In the general subgroup, LVH were more often observed at the C5, C4, and C3a stages of CKD (Table 4). In the subgroup of men, LVH was often detected at an early stage of CKD (C1, C2), while women with advanced stages of CKD (C3, C4) significantly increased the frequency of LVH.

Table 3: Echocardiographic indicators in the examined groups.

| Parameter                              | Total, n=945 | Female (n=360) | Male (n=585) | p<   |
|----------------------------------------|--------------|---------------|--------------|------|
| Relative wall thickness, units         | 0.371±0.06** | 0.366±0.06    | 0.374±0.05   | 0.05 |
| Normal LV geometry, n (%)              | 382 (40.4)   | 163 (45.2)    | 219 (37.4)   | 0.05 |
| Concentric Remodeling, n (%)           | 176 (18.6)   | 57 (15.8)     | 119 (20.3)   | 0.05 |

n = is the number of patients; p: is the reliability; ** - Mean ± SD; LV: left ventricle; LVH: left ventricular hypertrophy.

Table 4: The incidence of LVH at different stages of CKD.

| Stage of CKD | Total, n=387 | Female (LVH, n=178) | Male (LVH, n=209) | p <   |
|--------------|--------------|---------------------|-------------------|------|
| C1, n(%)     | 30 (7.8)     | 7 (3.9)             | 23 (11.0)         | 0.05 |
| C2, n(%)     | 35 (9.0)     | 11 (6.2)            | 24 (11.5)         | 0.05 |
| C3a, n(%)    | 58 (14.9)    | 31 (17.4)           | 27 (12.9)         | 0.26 |
| C3b, n(%)    | 38 (10.0)    | 25 (14.0)           | 13 (6.2)          | 0.05 |
| C4, n(%)     | 72 (18.6)    | 39 (21.9)           | 33 (15.8)         | 0.13 |
| C5, n(%)     | 154 (39.7)   | 65 (36.6)           | 89 (42.6)         | 0.23 |
| LVH, n(%)    | 387 (40.9)   | 178 (49.4)          | 209 (35.7)        | 0.05 |

LVH: left ventricular hypertrophy; CKD: chronic kidney disease; C: stage; p: is the reliability; n = is the number of patients.

It is noteworthy that the prevalence of LVH at the C5 stage of CKD in both the group of women and the group of men was similar. This served as the basis for the correlation analysis in each group, the results of which are shown in (Table 5).

There was no significant relationship between body mass index (BMI), sodium and total plasma protein with LVMI. In both subgroups, the level of systolic and diastolic blood pressure, concentrations of Hb and blood UA influenced LVH development (Table 5). An inverse reliable correlation was observed between the eGFR value and LVMI in both subgroups. It should be noted that a positive relationship was recorded...
between the daily excretion of protein with urine and the concentration of TC in blood plasma with LVMI in males, which was not observed in the group of women. As can be seen from (Table 5), the correlation relationship between blood pressure, blood UA concentration, and eGFR with LVMI were more pronounced in the subgroup of females.

**Table 5:** Correlation analysis between clinical and laboratory parameters and LVMI.

| Parameter                          | Female (n=360) | Male (n=585) |
|-----------------------------------|----------------|--------------|
|                                  | LVMI, g/m²     | r   | p   | r   | p   |
| Body mass index, kg / m²          | 0.142          | 0.192 | 0.548 | 0.467 |
| Systolic blood pressure, mmHg     | 0.591          | 0.001 | 0.484 | 0.001 |
| Diastolic blood pressure, mmHg    | 0.632          | 0.001 | 0.387 | 0.001 |
| Hemoglobin, g / l                 | -0.306         | 0.005 | -0.333 | 0.005 |
| Total cholesterol, mmol / l       | 0.176          | 0.111 | 0.312 | 0.005 |
| Uric acid, mmol / l               | 0.334          | 0.005 | 0.262 | 0.005 |
| Sodium, mmol / l                  | 0.061          | 0.582 | 0.097 | 0.197 |
| Total protein, g / l              | 0.113          | 0.335 | 0.127 | 0.091 |
| eGFR, ml / min                    | -0.410         | 0.001 | -0.363 | 0.005 |
| Proteinuria, g / day              | 0.196          | 0.075 | 0.272 | 0.005 |

LVMI: indexed mass of the left ventricular myocardium; eGFR: estimated glomerular filtration rate; n: is the number of patients; r: correlation; p: is the reliability

**Discussion**

In the structure of CVD with CKD, LVH occupies an important place. It is believed that LVH is initially formed as an adaptive process aimed at maintaining normal heart function under conditions of myocardial overload by pressure or volume, but then acquires the character of pathological adaptation, becoming the structural basis of heart failure, myocardial ischemia and cardiac arrhythmias [18]. It was shown that the probability of LVH increases already with a moderate decrease in eGFR and increases further as CKD progresses, reaching a maximum in the terminal stage [19]. This information was fully confirmed in our study, where in patients with CKD, the prevalence of LVH was higher at the C3, C4 and C5 stages of the disease (Table 4). Moreover, the incidence of LVH was significantly higher among females (Table 4). Apparently, this is explained by the fact that in the subgroup of women there were specific "renal" risk factors for the appearance of LVH [20].

In particular, in this subgroup, the Hb content, the number of red blood cells in the peripheral blood, and the eGFR value were significantly lower (Table 2). Anemia can be the main and not the only cause of LVH in patients with CKD [21]. Conversely, anemia correction in patients with CKD using erythropoietin is accompanied by a decrease in LV myocardial mass [22]. In turn, a decrease in eGFR doubles the risk of LVH in patients with anemia [19-22]. Anemic-hypoxic vasodilation increases the activity of the sympathetic nervous system, causing tachycardia and an increase in venous return with an increase in cardiac output [23]. Under conditions of anemia, the concentration of pro-inflammatory markers inducing LVH and fibrosis increases [24]. With anemia, the rate of arterial blood flow increases, there is a thickening of the walls of large arteries and a decrease in their compliance, the peak of systolic blood pressure increases, the shock and minute volumes of the heart increase, which leads to the development of mainly LVH of an eccentric type [25].

In our study, in the cohort of women, a widespread variant of LVH was its eccentric type (Table 3). In males, a concentric type of LVH was significantly more common. It should be noted that in the indicated cohort, according to the results of the correlation analysis, a direct relationship was noted between the concentration of blood plasma total cholesterol and proteinuria with LVMI (Table 5). In a previously published work by J. Ghali et al. (1991), results of a nine-year dynamic follow-up of patients with LVH were reported [26]. The authors showed that concentric LVH was associated with a higher risk of death than eccentric, although the influence on the prognosis of LV RWT was less significant than LVMI [26]. In the CRIC (The Chronic Renal Insufficiency Cohort) study, women found a 14% lower risk of LVH [27].

According to E. Paoletti et al., in a study of 445 patients with stages 2-5 of CKD with AH, it was found that age, female gender, anemia, and nocturnal hypertension were independently associated with both concentric and eccentric LVH, while diabetes and a history of cardiovascular disease is associated only with eccentric LVH, and stages 4 and 5 of CKD - only with concentric LVH [28]. P. Paoletti et al. (2016) found that the female gender was a strong predictor of LVH, as was shown in previous observations [28]. E. Paoletti et al. explain this fact by the independent effect of increased BMI in women, which is reported to have a greater effect on LVH compared with men, indeed, the BMI in the group of women was higher than in men while the prevalence of obesity was two times higher [29, 30].

A number of studies performed by other researchers have shown the effect of LV structural restructuring on the severity and prognosis of AH. Thus, the highest risk indicators for CVC and mortality were observed in patients of participants in the Framingham study with concentric LVH [31, 32]. Proteinuria is a recognized risk factor for LVH in CKD. Our study demonstrated a direct relationship between the severity of proteinuria and the growth of LVMI (Table 5). The relationship between LVH and proteinuria is realized through other risk factors associated with CKD, such as hypercholesterolemia (HCS) [33]. There is evidence that hyper- and dyslipidemia make an additional contribution to the development of LV remodeling [31]. In CKD, as eGFR decreases, in the presence of proteinuria and HCS, atherosclerosis and associated impaired arterial elasticity accelerate, which is accompanied by an increase in vascular resistance and the occurrence of LVH [34].

A. Vallee et al. showed an increase in arterial stiffness and its association with LVH in a population of people with CKD [35]. Arterial stiffness is mainly due to an increase in collagen production and deposition, followed by an increase in peripheral resistance due to vasocostriction [36]. Rrigidity can also be caused by an increase in plasma sodium concentration (>135 mmol/l), which directly affects the release of vascular endothelium and nitric oxide [37, 38]. Modulation of plasma sodium concentration during dialysis sessions can have a positive effect on blood pressure and left ventricular compliance [39, 40]. Based on the information obtained by us, it should be noted that LVH for CKD is multifactorial in nature and may be gender specific. So, in women with the progression of CKD, the development of LVH is predominantly caused by hypertension, anemia, and hyperuricemia. In men with CKD,
hypercholesterolemia and daily urinary protein excretion make an additional contribution to the development of LVH of predominantly concentric types.

Conclusion

The prevalence of LVH in CKD was 40.9%. Among females, the incidence of LVH was higher (49.4%). The predominant type of LV remodeling in the female population was eccentric (79.2%), and among men, concentric (39.7%). A direct correlation of the severity of LVH with arterial hypertension, anemic syndrome and hyperuricemia in women, and in men with the values of dyslipidemia and daily proteinuria, requires, in the early stages of the disease, timely correction of these factors for the progression of CKD and the development of cardiovascular complications.

Funding

None.

Disclosures

None.

REFERENCES

1. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A et al. (2020) Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic approach for the Global Burden of Disease Study 2017. Lancet 395: 709-733. [Crossref]
2. Kelly L, Matsumoto CL, Schreiber Y, Gordon J, Willms H et al. (2019) Prevalence of chronic kidney disease and cardiovascular comorbidities in adults in First Nations communities in northwest Ontario: a retrospective observational study. CMAJ Open 7: E568-E572. [Crossref]
3. Reichel H, Zee J, Tu C, Young E, Pisoni RL et al. (2020) Chronic kidney disease progression and mortality risk profiles in Germany: results from the Chronic Kidney Disease Outcomes and Practice Patterns Study. Nephrol Dial Transplant 260. [Crossref]
4. Ronco C. (2011) The Cardiorenal Syndrome: Basis and Common Ground for a Multidisciplinary Patient-Oriented Therapy. Cardiorenal Med 1: 3-4. [Crossref]
5. Hu MC, Scanni R, Ye J, Zhang J, Shi M et al. (2020) Dietary vitamin D interacts with high phosphate-induced cardiac remodeling in rats with normal renal function. Nephrol Dial Transplant 35: 411-421. [Crossref]
6. Nitta K, Imuro S, Imae E, Matsuo S, Makino H et al. (2019) Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: findings from the CKD-JAC study. Clin Exp Nephrol 23: 85-98. [Crossref]
7. Wu J, Liu W, Cao H (2020) Cardiovascular disease in chronic kidney disease. Chronic Kidney Disease. Springer Singapore 111-121.
8. Kaesler N, Babler A, Floege J, Kramann R (2020) Cardiac Remodeling in Chronic Kidney Disease. Toxins (Basel) 12: E161. [Crossref]
9. Bortomeu Gonzalez V, Moreno Arribas J, Esteve Pastor MA, Roldán Rabadán I, Muñiz J et al. (2020) Association of Body Mass Index With Clinical Outcomes in Patients With Atrial Fibrillation: A Report From the FANTASIIA Registry. J Am Heart Assoc 9: e013789. [Crossref]
10. Fonmina IG, Dyakova TA (2006) Left ventricular hypertrophy in arterial hypertension and arrhythmia risk. Cardiovas Ther Preven 5: 83-89.
11. Temimovitch R, Rašić S, Đubur A (2019) Cardiovascular remodelling in patients with pre-dialysis chronic kidney disease and renal transplant recipients. Med Glas (Zenica) 16. [Crossref]
12. Vankayala A, Behera KL, Raju DSKR, Sayana SB (2019) A study on the left ventricular hypertrophy among the patients of chronic kidney disease stage third to five. Int J Res Med Sci 7: 1511.
13. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39: S1-S266. [Crossref]
14. Levey AS, Stevens LA, Schmid CH, Kusek JW, Coresh J et al. (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612. [Crossref]
15. Elliseev MS (2014) New international recommendations for the diagnosis and treatment of gout. Rheumatol Sci Pract 52: 141-146.
16. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E et al. (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57: 450-458. [Crossref]
17. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A et al. (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Cardiology (ESC). J Hypertens 31: 1281-1357. [Crossref]
18. Barbarash OL, Mulerova TA, Maksimov VN, Chigisova AN, Voevod MI et al. (2018) Left Ventricular Myocardial Hypertrophy as a Result of Arterial Hypertension Among Mountain Shoria Population. The Role of Genetic Polymorphism. Kardiologiya 58: 37-46. [Crossref]
19. Cerasola G, Nardi E, Palermo A, Mulè G, Cottone S (2011) Epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: a review. J Nephrol 24: 1-10. [Crossref]
20. Moiseev VC, Mukhin NA (2014) Cardiovascular risk and chronic kidney disease: cardio- and nephroprotection strategies. Clin Nephrol 2: 4-29.
21. Abramovitz B, Berns JS (2020) Management of Anemia in Chronic Kidney Disease. Chronic Renal Disease. Academic Press 991-1000.
22. Dobronarov VA, Smirnov AV, Bezrukkh AH, Bystrova NN, Drozdova YY et al. (2006) Anemia and pre-dialysis stages of chronic kidney disease: clinical significance, incidence and risk factors. Nephrology (Saint-Petersburg) 10: 7-13.
23. Gupta K, Kalra R, Rajapure Y, Joly JM, Pate M et al. (2020) Anemia, Mortality, and Hospitalizations in Heart Failure With a Preserved Ejection Fraction (from the TOPCAT Trial). Am J Cardiol. [Crossref]
24. Gluba Brzózka A, Franciszk B, Olszewski R, Rysz J (2020) The Influence of Inflammation on Anemia in CKD Patients. Int J Mol Sci 21: E725. [Crossref]
25. House AA, Ronco C, Herzog CA (2020) Chronic Kidney Disease and Heart Failure - A Nephrologic Approach. Chronic Renal Disease. Academic Press 883-897.
26. Ghali J, Kadakia S, Cooper R, Liao YL (1991) Impact of left ventricular hypertrophy patterns on ventricular arrhythmias in the absence of coronary artery disease. J Am Coll Cardiol 17: 1277-1282. [Crossref]
27. Bansal N, Keane M, Delafontaine P, Dries D, Foster E et al. (2013) A longitudinal study of left ventricular function and structure from CKD to ESRD: the CRIC study. Clin J Am Soc Nephrol 8: 355-362. [Crossref]
28. Paoletti E, De Nicola L, Gabbai FB, Chiodini P, Ravera M et al. (2016) Associations of Left Ventricular Hypertrophy and Geometry with
Adverse Outcomes in Patients with CKD and Hypertension. *Clin J Am Soc Nephrol* 11: 271-279. [Crossref]

29. Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G (2005) Left ventricular hypertrophy in nondiabetic predialysis CKD. *Am J Kidney Dis* 46: 320-327. [Crossref]

30. Paoletti E, Bellino D, Gallina AM, Amidone M, Cassottana P et al. (2011) Is left ventricular hypertrophy a powerful predictor of progression to dialysis in chronic kidney disease? *Nephrol Dial Transplant* 26: 670-677. [Crossref]

31. Julien J, Tranche C, Souchet T (2004) Left ventricular hypertrophy in hypertensive patients. Epidemiology and prognosis. *Arch Mal Coeur Vaiss* 97: 221-227. [Crossref]

32. Krumholz HM, Larson M, Levy D (1995) Prognosis of left ventricular geometric patterns in the Framingham Heart Study. *J Am Coll Cardiol* 25: 879-884. [Crossref]

33. Barsukov AV, Zobnina MP, Talantseva MS (2012) Left ventricular hypertrophy and outcomes: A five-year retrospective analysis of patients with essential hypertension. "Arterial'naya Giptenziyia" ("Arterial Hypertension") 18: 385-397.

34. Mehta SK, Rame JE, Khera A, Murphy SA, Canham RM et al. (2007) Left ventricular hypertrophy, subclinical atherosclerosis, and inflammation. *Hypertension* 49: 1385-1391. [Crossref]

35. Vallée A, Cinaud A, Protogerou A, Zhang Y, Topouchian J et al. (2020) Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms. *Curr Hypertens Rep* 22: 5. [Crossref]

36. Lioufas NM, Pedagogos E, Hawley CM, Pascoe EM, Elder GI et al. (2020) Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial. *Am J Nephrol* 51: 201-215. [Crossref]

37. Bond V Jr, Becknel K, Kumar K, Dorsey J, Gorantla VR et al. (2019) Association of Endothelial Function with Parental Hypertension in Normotensive-Obese African-American Women: A Pilot Study. *Adv Prev Med* 2019: 5854219. [Crossref]

38. Omboni S (2020) Does Dietary Salt Loading Impair Ambulatory Blood Pressure Variability? As Yet an Unresolved Issue. *Am J Hypertens*. [Crossref]

39. Himmelsbach A, Ciliox C, Goettich C (2020) Cardiovascular Calcification in Chronic Kidney Disease-Therapeutic Opportunities. *Toxins (Basel)* 12: E181. [Crossref]

40. Reshetnik A, Wrobel D, Wirtz G, Tölle M, Eckardt KU et al. (2020) True Arterial Stiffness Does Not Change between Dialysis Sessions during 1 Week in Outpatients on Intermittent Hemodialysis. *Kidney Blood Press Res* 45: 51-60. [Crossref]